Angiotensin (1-7) vs Cerluten

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

Angiotensin-(1-7) [Ang-(1-7)] is an endogenous heptapeptide hormone generated primarily through cleavage of angiotensin II by ACE2, functioning as a counter-regulatory arm of the renin-angiotensin system (RAS) by binding the Mas receptor to promote vasodilation, anti-fibrotic, anti-inflammatory, and cardioprotective effects that oppose the vasoconstrictive actions of angiotensin II. Ang-(1-7) acts through the ACE2/Mas receptor axis to reduce oxidative stress, attenuate NF-kB-mediated inflammation, and suppress TGF-beta fibrosis signaling; the ACE2/Ang-(1-7)/Mas axis has emerged as a key regulatory pathway in cardiovascular and metabolic disease, and gained renewed research attention given ACE2's role as the SARS-CoV-2 entry receptor. A Phase 1-2 randomized clinical trial of Ang-(1-7) infusion in COVID-19 ICU patients reported preliminary safety, tolerability, and dose-response data, providing the primary indexed human pharmacokinetic evidence; broader cardiovascular protective applications are supported by preclinical data but have not been established by completed Phase 3 trials. Ang-(1-7) has no FDA approval and no approved therapeutic indication in any jurisdiction; it is an endogenous peptide under active clinical investigation as a candidate for cardiovascular, metabolic, and inflammatory conditions, with emerging human safety data but an incomplete evidence base for any specific approved clinical use.

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Cerluten is a synthetic short peptide classified as a Khavinson-class bioregulator targeted at cerebral and central nervous system tissue, investigated for neuroprotective and anti-aging properties in neuronal cell populations through proposed gene expression regulatory mechanisms. Like other Khavinson bioregulator peptides, cerluten is proposed to reach target neuronal cells via amino acid transporter uptake — including proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT) — and to modulate transcriptional activity in aging or damaged neural tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport via POT and LAT carriers and demonstrated gene expression regulatory effects across multiple tissue types, providing the class-level mechanistic framework within which cerluten's neuronal effects are proposed. Cerluten has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Cerluten dosing and respiratory applications Cerluten is classified as a bronchial tissue bioregulator in the Khavinson peptide research tradition, proposed to act on bronchial epithelial cells via amino acid transporter uptake and modulate gene expression related to respiratory tissue maintenance and oxidative stress response in aging airways. Preclinical and observational research in Eastern European clinical settings has examined cerluten in contexts of chronic bronchitis, age-related decline in respiratory function, and COPD support, with proposed mechanisms including anti-inflammatory gene regulation and bronchial epithelial cell cytoprotection. Standard Khavinson-class dosing protocols use oral capsule formulations in 10–20 day cycles at 5–10mg per cycle (divided doses), followed by rest intervals — consistent with the gene-regulatory rather than continuous-receptor-occupancy mechanism proposed for this peptide class. Independent peer-reviewed clinical trial evidence specific to cerluten is limited; efficacy data comes primarily from Khavinson Institute publications and observational reports. Cerluten is available from specialty Eastern European supplement and peptide vendors and is not approved by the FDA or EMA as a pharmaceutical. It is distinct from Chonluten, which targets lung parenchyma rather than bronchial epithelial tissue.